BioAge Labs (NASDAQ:BIOA) Trading Down 8.7% – What’s Next?

BioAge Labs, Inc. (NASDAQ:BIOA) fell 8.7% on Monday . The stock traded as low as $16.26 and last traded at $16.12. 107,037 shares traded hands during trading, a decline of 83% from the average session volume of 621,039 shares. The stock had previously closed at $17.66.

Analyst Ratings Changes

A number of equities analysts recently issued reports on the company. Morgan Stanley set a $23.00 price target on BioAge Labs in a report on Wednesday, February 4th. Oppenheimer assumed coverage on shares of BioAge Labs in a research report on Wednesday, February 25th. They set an “outperform” rating and a $60.00 price objective for the company. Citigroup upped their target price on shares of BioAge Labs from $15.00 to $52.00 and gave the company a “buy” rating in a report on Tuesday, March 10th. BTIG Research assumed coverage on shares of BioAge Labs in a research report on Wednesday, May 13th. They issued a “buy” rating and a $40.00 target price on the stock. Finally, Wall Street Zen lowered shares of BioAge Labs from a “hold” rating to a “sell” rating in a research note on Sunday. Five investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, BioAge Labs presently has a consensus rating of “Moderate Buy” and a consensus target price of $45.00.

BioAge Labs Trading Down 12.5%

The stock has a market cap of $686.53 million, a PE ratio of -6.44 and a beta of 0.99. The business has a 50 day moving average of $18.15 and a 200-day moving average of $15.88.

BioAge Labs (NASDAQ:BIOA) last issued its quarterly earnings data on Friday, May 8th. The company reported ($0.52) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.71) by $0.19. The company had revenue of $2.77 million during the quarter. BioAge Labs had a negative return on equity of 29.40% and a negative net margin of 871.75%. Research analysts expect that BioAge Labs, Inc. will post -2.59 EPS for the current fiscal year.

Institutional Trading of BioAge Labs

Large investors have recently bought and sold shares of the business. Octagon Capital Advisors LP grew its position in BioAge Labs by 9.4% during the 1st quarter. Octagon Capital Advisors LP now owns 1,748,000 shares of the company’s stock worth $30,573,000 after purchasing an additional 150,000 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of BioAge Labs by 6.0% during the third quarter. Vanguard Group Inc. now owns 1,651,247 shares of the company’s stock worth $9,709,000 after buying an additional 93,694 shares during the period. Adage Capital Partners GP L.L.C. purchased a new position in shares of BioAge Labs during the fourth quarter worth about $13,892,000. Geode Capital Management LLC grew its holdings in shares of BioAge Labs by 5.1% during the fourth quarter. Geode Capital Management LLC now owns 591,377 shares of the company’s stock worth $7,826,000 after buying an additional 28,646 shares during the last quarter. Finally, State Street Corp increased its position in BioAge Labs by 113.4% in the 4th quarter. State Street Corp now owns 422,846 shares of the company’s stock valued at $5,594,000 after acquiring an additional 224,735 shares during the period.

BioAge Labs Company Profile

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.